Patrick M Meyer Sauteur1, Selina Krautter1, Lilliam Ambroggio2, Michelle Seiler3, Paolo Paioni1, Christa Relly1, Riccarda Capaul4, Christian Kellenberger5, Thorsten Haas6, Claudine Gysin7, Lucas M Bachmann8, Annemarie M C van Rossum9, Christoph Berger1. 1. Division of Infectious Diseases and Hospital Epidemiology, University Children's Hospital Zurich, Zurich, Switzerland. 2. Emergency Medicine and Hospital Medicine, Children's Hospital Colorado, Denver, Colorado, USA. 3. Emergency Department, University Children's Hospital Zurich, Zurich, Switzerland. 4. Institute of Medical Virology, University of Zurich, Zurich, Switzerland. 5. Division of Diagnostic Imaging, University Children's Hospital Zurich, Zurich, Switzerland. 6. Division of Anesthesiology, University Children's Hospital Zurich, Zurich, Switzerland. 7. Division of Otolaryngology, University Children's Hospital Zurich, Zurich, Switzerland. 8. Medignition Inc Research Consultants, Zurich, Switzerland. 9. Department of Pediatrics, Division of Pediatric Infectious Diseases and Immunology, Erasmus MC University Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.
Abstract
BACKGROUND: There are no reliable signs or symptoms that differentiate Mycoplasma pneumoniae (Mp) infection in community-acquired pneumonia (CAP) from other etiologies. Additionally, current diagnostic tests do not reliably distinguish between Mp infection and carriage. We previously determined that the measurement of Mp-specific immunoglobulin M antibody-secreting cells (ASCs) by enzyme-linked immunospot assay allowed for differentiation between infection and carriage. Using this new diagnostic test, we aimed to identify clinical and laboratory features associated with Mp infection. METHODS: This is a prospective cohort study of children, 3-18 years of age, with CAP from 2016 to 2017. Clinical features and biomarkers were compared between Mp-positive and -negative groups by Mann-Whitney U test or Fisher exact test, as appropriate. Area under the receiver operating characteristic curve (AUC) differences and optimal thresholds were determined by using the DeLong test and Youden J statistic, respectively. RESULTS: Of 63 CAP patients, 29 were Mp-positive (46%). Mp positivity was statistically associated with older age (median, 8.6 vs 4.7 years), no underlying disease, family with respiratory symptoms, prior antibiotic treatment, prolonged prodromal respiratory symptoms and fever, and extrapulmonary (skin) manifestations. Lower levels of C-reactive protein, white blood cell count, absolute neutrophil count, and procalcitonin (PCT), specifically PCT <0.25 μg/L, were statistically associated with Mp infection. A combination of age >5 years (AUC = 0.77), prodromal fever and respiratory symptoms >6 days (AUC = 0.79), and PCT <0.25 μg/L (AUC = 0.81) improved diagnostic performance (AUC = 0.90) (P = .05). CONCLUSIONS: A combination of clinical features and biomarkers may aid physicians in identifying patients at high risk for Mp CAP.
BACKGROUND: There are no reliable signs or symptoms that differentiate Mycoplasma pneumoniae (Mp) infection in community-acquired pneumonia (CAP) from other etiologies. Additionally, current diagnostic tests do not reliably distinguish between Mp infection and carriage. We previously determined that the measurement of Mp-specific immunoglobulin M antibody-secreting cells (ASCs) by enzyme-linked immunospot assay allowed for differentiation between infection and carriage. Using this new diagnostic test, we aimed to identify clinical and laboratory features associated with Mp infection. METHODS: This is a prospective cohort study of children, 3-18 years of age, with CAP from 2016 to 2017. Clinical features and biomarkers were compared between Mp-positive and -negative groups by Mann-Whitney U test or Fisher exact test, as appropriate. Area under the receiver operating characteristic curve (AUC) differences and optimal thresholds were determined by using the DeLong test and Youden J statistic, respectively. RESULTS: Of 63 CAP patients, 29 were Mp-positive (46%). Mp positivity was statistically associated with older age (median, 8.6 vs 4.7 years), no underlying disease, family with respiratory symptoms, prior antibiotic treatment, prolonged prodromal respiratory symptoms and fever, and extrapulmonary (skin) manifestations. Lower levels of C-reactive protein, white blood cell count, absolute neutrophil count, and procalcitonin (PCT), specifically PCT <0.25 μg/L, were statistically associated with Mp infection. A combination of age >5 years (AUC = 0.77), prodromal fever and respiratory symptoms >6 days (AUC = 0.79), and PCT <0.25 μg/L (AUC = 0.81) improved diagnostic performance (AUC = 0.90) (P = .05). CONCLUSIONS: A combination of clinical features and biomarkers may aid physicians in identifying patients at high risk for Mp CAP.
Authors: T R Kannan; R D Hardy; J J Coalson; D C Cavuoti; J D Siegel; M Cagle; O Musatovova; C Herrera; J B Baseman Journal: Clin Infect Dis Date: 2011-11-03 Impact factor: 9.079
Authors: Thomas Cherian; E Kim Mulholland; John B Carlin; Harald Ostensen; Ruhul Amin; Margaret de Campo; David Greenberg; Rosanna Lagos; Marilla Lucero; Shabir A Madhi; Katherine L O'Brien; Steven Obaro; Mark C Steinhoff Journal: Bull World Health Organ Date: 2005-06-24 Impact factor: 9.408
Authors: Eric Biondi; Russell McCulloh; Brian Alverson; Andrew Klein; Angela Dixon; Shawn Ralston Journal: Pediatrics Date: 2014-06 Impact factor: 7.124
Authors: Patrick M Meyer Sauteur; Martin Theiler; Michael Buettcher; Michelle Seiler; Lisa Weibel; Christoph Berger Journal: JAMA Dermatol Date: 2020-02-01 Impact factor: 10.282
Authors: Seema Jain; Derek J Williams; Sandra R Arnold; Krow Ampofo; Anna M Bramley; Carrie Reed; Chris Stockmann; Evan J Anderson; Carlos G Grijalva; Wesley H Self; Yuwei Zhu; Anami Patel; Weston Hymas; James D Chappell; Robert A Kaufman; J Herman Kan; David Dansie; Noel Lenny; David R Hillyard; Lia M Haynes; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Richard G Wunderink; Kathryn M Edwards; Andrew T Pavia; Jonathan A McCullers; Lyn Finelli Journal: N Engl J Med Date: 2015-02-26 Impact factor: 91.245
Authors: Emiel B M Spuesens; Pieter L A Fraaij; Eline G Visser; Theo Hoogenboezem; Wim C J Hop; Léon N A van Adrichem; Frank Weber; Henriette A Moll; Berth Broekman; Marjolein Y Berger; Tineke van Rijsoort-Vos; Alex van Belkum; Martin Schutten; Suzan D Pas; Albert D M E Osterhaus; Nico G Hartwig; Cornelis Vink; Annemarie M C van Rossum Journal: PLoS Med Date: 2013-05-14 Impact factor: 11.069
Authors: R C A de Groot; H Zhu; T Hoogenboezem; A C J M de Bruijn; E Eenjes; A E J 't Jong; A I Belo; S C Estevão; J J Bajramovic; R J Rottier; M Kool; A M C van Rossum; W W J Unger Journal: Infect Immun Date: 2022-07-11 Impact factor: 3.609
Authors: Christoph Berger; Roger Dumke; Patrick M Meyer Sauteur; Elena Pánisová; Michelle Seiler; Martin Theiler Journal: J Clin Microbiol Date: 2021-06-18 Impact factor: 5.948
Authors: Patrick M Meyer Sauteur; Michael L Beeton; Søren A Uldum; Nathalie Bossuyt; Melissa Vermeulen; Katherine Loens; Sabine Pereyre; Cécile Bébéar; Darja Keše; Jessica Day; Baharak Afshar; Victoria J Chalker; Gilbert Greub; Ran Nir-Paz; Roger Dumke Journal: Euro Surveill Date: 2022-05